Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.
In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...
Daily Express US on MSN5d
Eye drops claiming to change eye color raise alarm among eye specialists on TikTokOphthalmic surgeon Dr. Ali Mearza has urged people to "prioritise their health over trends" as he warns of the dangers of ...
Researchers Jennifer Loh, MD, of Loh Ophthalmology Associates in Glenvar Heights, Florida, and Preeya Gupta, MD, of Triangle Eye Associates in Raleigh, North Carolina evaluated 613 patients between 45 ...
GlobalData on MSN5d
FDA delays priority review of Neurotech’s eye cell therapy implantThe US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...
A drug-eluting contact lens that uses 3D printing technology can improve IOP and treatment compliance for patients with glaucoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback